Redx Pharma Plc (REDX)

London
121.00
-1.50(-1.23%)
  • Volume:
    136,564
  • Bid/Ask:
    120.00/121.00
  • Day's Range:
    129.50 - 129.50

REDX Overview

Prev. Close
122
Day's Range
129.5-129.5
Revenue
6.61M
Open
124
52 wk Range
48.4-129.9
EPS
-0.08
Volume
136,564
Market Cap
335.23M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
83,021
P/E Ratio
-
Beta
0.3
1-Year Change
100.1%
Shares Outstanding
274,782,205
Next Earnings Date
25 Jan 2022
What is your sentiment on Redx Pharma Plc?
or
Vote to see community's results!

Redx Pharma Plc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellSellStrong BuyStrong BuyStrong Buy
SummaryNeutralNeutralStrong BuyStrong BuyStrong Buy

Redx Pharma Plc Company Profile

Redx Pharma Plc Company Profile

Employees
52

Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.